

Serum Amyloid A as a prognostic marker for disease severity and mortality in COVID-19

No registrations found.

Ethical review	Not applicable
Status	Pending
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON20323

Source

NTR

Brief title

SAVID

Health condition

COVID-19

Sponsors and support

Primary sponsor: Board of Directors Franciscus Gasthuis & Vlietland

Source(s) of monetary or material Support: Siemens Healthcare Gmbh

Intervention

Outcome measures

Primary outcome

Difference in sensitivity of blood plasma SAA, CRP , ferritin and PCT levels on day 1, day 3, day 5 and day 7 of hospital stay in patients with severe versus non-severe COVID-19 disease course.

Secondary outcome

- Specificity, positive and negative predictive values, positive and negative likelihood ratios SAA versus CRP, ferritin and PCT.
- Clinical course of COVID-19 including classification of COVID-19 severity according to the WHO criteria (Clinical management of COVID-19 (who.int)).
- Disease outcome at time of hospital discharge (or death).

Study description

Background summary

The goal of this study is to investigate recent claims from Chinese studies that serum amyloid A (SAA) is a superior prognostic inflammatory marker in COVID-19 when compared to CRP, ferritin and PCT on day 1, day 3, day 5 and day 7 of hospital admission.

Study objective

SAA is superior to CRP, ferritin and procalcitonin as prognostic inflammatory marker in COVID-19

Study design

d1, d3, d5, d7

Intervention

None

Contacts

Public

Franciscus Gasthuis & Vlietland
Nadine Pouw

0031 10 4616091

Scientific

Franciscus Gasthuis & Vlietland
Nadine Pouw

0031 10 4616091

Eligibility criteria

Inclusion criteria

18 jaar or older;
hospitalised for (suspicion of) COVID-19;
written informed consent for those subjects admitted to the non-ICU clinical COVID-19 ward.

Exclusion criteria

Subjects undergoing experimental interventions will be excluded.

Study design

Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-01-2021
Enrollment:	350
Type:	Anticipated

IPD sharing statement

Plan to share IPD: Undecided

Ethics review

Not applicable

Application type:

Not applicable

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL9082
Other	MEC-U : not yet available

Study results